Edition:
United States

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

164.61USD
26 Apr 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$164.61
Open
--
Day's High
--
Day's Low
--
Volume
13,269
Avg. Vol
1,223,311
52-wk High
$184.20
52-wk Low
$133.64

AMGN.OQ

Chart for AMGN.OQ

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.28
Market Cap(Mil.): $121,134.90
Shares Outstanding(Mil.): 735.89
Dividend: 1.15
Yield (%): 2.79

Financials

  AMGN.OQ Industry Sector
P/E (TTM): 15.60 58.41 30.30
EPS (TTM): 10.55 -- --
ROI: 11.79 0.45 13.24
ROE: 26.61 6.31 14.40

India watchdog orders antitrust probe into Roche cancer drug

MUMBAI India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients.

6:33am EDT

UPDATE 1-India watchdog orders antitrust probe into Roche cancer drug

MUMBAI, April 27 India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients.

6:29am EDT

Cost controls help offset lower Amgen first-quarter drug sales

Amgen Inc on Wednesday reported higher-than-expected first-quarter profit as cost controls helped offset a sharp drop in sales of Enbrel, its blockbuster rheumatoid arthritis and psoriasis drug.

Apr 26 2017

BRIEF-Amgen reports Q1 GAAP earnings per share $2.79

* Says 2017 earnings per share guidance increased to $10.64-$11.32 on GAAP basis, and $12.00-$12.60 on non-GAAP basis

Apr 26 2017

UPDATE 3-Cost controls help offset lower Amgen 1st-quarter drug sales

April 26 Amgen Inc on Wednesday reported higher-than-expected first-quarter profit as cost controls helped offset a sharp drop in sales of Enbrel, its blockbuster rheumatoid arthritis and psoriasis drug.

Apr 26 2017

BRIEF-Amgen optimistic for Enbrel sales rebound

* Amgen says optimistic about rebound in Enbrel sales in coming quarters after Q1 decline

Apr 26 2017

Amgen first-quarter profit exceeds Street estimates on lower costs

April 26 Amgen Inc on Wednesday reported higher-than-expected first-quarter profit as cost controls helped offset a sharp drop in sales of Enbrel, its blockbuster rheumatoid arthritis and psoriasis drug.

Apr 26 2017

BRIEF-Coherus Biosciences completes formalities with amgen for Coherus' CHS-1701

* Completed initial phases of biologics price competition & innovation act patent exchange procedure with amgen for Coherus' CHS-1701

Apr 25 2017

BRIEF-Amgen announces expanded commercial collaboration with Novartis for erenumab in migraine

* Amgen announces expanded commercial collaboration with Novartis for erenumab in migraine

Apr 24 2017

BRIEF-Amgen says CEO Robert Bradway's total compensation for 2016 was $16.9 mln vs $16.1 mln in 2015 - SEC filing

* Amgen Inc - CEO Robert Bradway's total compensation for 2016 was $16.9 million versus $16.1 million in 2015 - SEC filing Source text: (http://bit.ly/2oOpF0j) Further company coverage:

Apr 06 2017

More From Around the Web

Earnings vs. Estimates